product name
TAPI-0, TAPI-0, CAS 143457-40-3, is a hydroxamate-based inhibitor of collagenase, gelatinase, and TACE (TNF-α converting enzyme/ADAM17; IC₅₀ = 100 nM).
品質等級
化驗
≥96% (HPLC)
形狀
solid
製造商/商標名
Calbiochem®
儲存條件
OK to freeze
desiccated (hygroscopic)
protect from light
顏色
white
溶解度
50% acetic acid: 1 mg/mL
DMSO: 5 mg/mL
運輸包裝
ambient
儲存溫度
−20°C
InChI
1S/C24H32N4O5/c1-14(2)10-19(13-21(29)28-33)23(31)27-20(24(32)26-15(3)22(25)30)12-16-8-9-17-6-4-5-7-18(17)11-16/h4-9,11,14-15,19-20,33H,10,12-13H2,1-3H3,(H2,25,30)(H,26,32)(H,27,31)(H,28,29)/t15-,19?,20-/m0/s1
InChI 密鑰
CRCPLBFLOSEABN-VBSNWNEZSA-N
一般說明
A hydroxamate-based inhibitor of collagenase, gelatinase, and TACE (TNF-α converting enzyme/ADAM17; IC50 = 100 nM). Blocks spontaneous and PMA-induced release of TNF-α in transfected COS 7 cells.
A hydroxymate-based inhibitor of collagenase, gelatinase, and TACE [(TNF-α convertase; ADAM17 (IC50 = 100 nM)]. Blocks spontaneous and PMA-induced release of TNF-α from transfected COS-7 cells.
生化/生理作用
Cell permeable: no
Primary Target
TNF-α converting enzyme/ADAM17
TNF-α converting enzyme/ADAM17
Product does not compete with ATP.
Reversible: no
Target IC50: 100 nM against TACE (TNF-α converting enzyme/ADAM17)
包裝
Packaged under inert gas
警告
Toxicity: Standard Handling (A)
重構
Following reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 1 month at -20°C.
其他說明
Hooper, N.M., et al. 1997. Biochem. J.321, 265.
Mullberg, J., et al. 1995. J. Immunol.155, 5198.
Mohler, K.M., et al. 1994. Nature370, 218.
Mullberg, J., et al. 1995. J. Immunol.155, 5198.
Mohler, K.M., et al. 1994. Nature370, 218.
法律資訊
Manufactured exclusively by Peptides International, Louisville, Kentucky, USA.
CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany
儲存類別代碼
11 - Combustible Solids
水污染物質分類(WGK)
WGK 1
閃點(°F)
Not applicable
閃點(°C)
Not applicable
其他客户在看
European journal of immunology, 50(10), 1537-1549 (2020-05-12)
The IL-7 receptor specific α chain, CD127, can be expressed both as a membrane-associated (mCD127) and a soluble form (sCD127), however, the mechanisms involved in their regulation remain to be defined. We first demonstrated in primary human CD8+ T cells
BMC biology, 18(1), 60-60 (2020-06-05)
Epithin/PRSS14, a type II transmembrane serine protease, is an emerging target of cancer therapy because of its critical roles in tumor progression and metastasis. In many circumstances, the protease, through its ectodomain shedding, exists as a soluble form and performs
我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系技术服务部门